PD-L1 검사 시장 : 전략적 인사이트와 예측(2026-2035년)

The PD-L1 Testing Market is expected to grow at a CAGR of 7.5% from a market value of USD 1.27 billion in 2026 to USD 2.45 billion in 2035.

The PD-L1 testing market is undergoing significant transformation driven by the paradigm shift toward biomarker-guided immunotherapy and precision oncology. The market's evolution is characterized by the growing recognition that PD-L1 expression serves as a predictive biomarker for immune checkpoint inhibitor response across multiple solid tumors. The convergence of validated immunohistochemistry assays, digital pathology, and artificial intelligence is enabling more standardized and reproducible biomarker assessment. Healthcare systems are increasingly integrating PD-L1 testing into routine diagnostic pathways because treatment selection for immunotherapies directly depends on biomarker accuracy. Clinical adoption is extending beyond metastatic disease because immunotherapy is moving into earlier treatment settings, including neoadjuvant and adjuvant therapy, increasing testing volumes in pathology laboratories. Regulatory agencies continue strengthening the role of companion diagnostics in oncology drug approvals, creating a structural dependency between pharmaceutical development and diagnostic commercialization. The market is witnessing significant investment in automated staining platforms, digital pathology solutions, and multiplex biomarker technologies, positioning PD-L1 testing as a foundational component of precision oncology across increasingly heterogeneous cancer populations.

Market Drivers

The expanding immunotherapy indications represent the primary driver for the PD-L1 testing market. PD-L1 testing remains closely linked to the expanding clinical use of immune checkpoint inhibitors across oncology. Pharmaceutical sponsors are obtaining approvals for additional tumor types and earlier treatment settings, increasing the number of patients requiring biomarker evaluation before therapy initiation. This expansion creates sustained demand for validated companion diagnostic assays that demonstrate analytical reproducibility and regulatory compliance, resulting in sustained growth in PD-L1 testing utilization. The companion diagnostic co-development model is further accelerating market growth. Companion diagnostics represent an essential component of oncology drug development because regulatory authorities frequently require validated biomarkers during therapeutic approval. Pharmaceutical developers are integrating diagnostic partners into clinical development programs earlier to streamline regulatory submissions and accelerate commercial launches. This co-development model encourages long-term partnerships between pharmaceutical companies and diagnostic manufacturers while enabling synchronized regulatory submissions. Digital pathology adoption is improving diagnostic standardization and laboratory efficiency. Interpretation variability remains a significant challenge for PD-L1 immunohistochemistry because different scoring algorithms and observer experience may influence clinical decisions. Healthcare systems increasingly recognize the importance of standardized interpretation to ensure consistent patient eligibility across institutions. Diagnostic companies are integrating artificial intelligence-assisted image analysis with digital pathology platforms to improve scoring reproducibility and laboratory efficiency. Multiplex biomarker assessment is reshaping precision oncology by enabling broader biological insight. Cancer biology increasingly reflects complex interactions between tumor genomics and the immune microenvironment. Single biomarker evaluation provides only partial insight into therapeutic response, encouraging broader adoption of multiplex diagnostic approaches that integrate PD-L1 with complementary biomarkers, including tumor mutational burden and immune gene expression signatures.

Market Restraints

Variability among PD-L1 assays, antibody clones, scoring algorithms, and companion diagnostic requirements continues to limit result harmonization across laboratories. The lack of standardized protocols creates challenges for consistent interpretation and clinical confidence. Tissue availability remains constrained in several advanced cancers, reducing testing opportunities and increasing the need for repeat biopsy procedures. Limited tissue samples can restrict the ability to perform comprehensive biomarker assessment. High implementation costs for digital pathology infrastructure, automated staining systems, and quality assurance programs continue restricting adoption in resource-limited healthcare settings. The significant investment required for advanced instrumentation and expertise creates barriers for smaller laboratories. Regulatory complexities across different jurisdictions create compliance burdens for diagnostic manufacturers seeking to commercialize new testing solutions. The evolving regulatory landscape requires continuous adaptation, increasing operational costs and time-to-market for new products.

Technology and Segment Insights

The technology landscape is characterized by the growing importance of integrated pathology workflows. Immunohistochemistry remains the clinical standard for PD-L1 assessment because virtually all approved companion diagnostics rely on validated IHC assays linked to regulatory-approved immunotherapies. Demand is expanding as hospitals continue integrating biomarker-guided treatment pathways into routine oncology practice, increasing the need for standardized tissue-based testing. Digital pathology adoption is expanding because laboratories require scalable interpretation workflows that reduce interobserver variability. Multiplex immunofluorescence and spatial biology technologies are gaining clinical relevance as oncologists increasingly evaluate PD-L1 alongside genomic, immune, and transcriptomic biomarkers. The segment analysis reveals that assay kits and reagents represent the largest demand center because every patient evaluation requires standardized consumables regardless of laboratory size or testing frequency. Clinical adoption is increasing as immune checkpoint inhibitors receive approvals across additional tumor types, causing pathology laboratories to process higher testing volumes. Lung cancer represents the largest clinical application because immune checkpoint inhibitors constitute a major treatment option for both metastatic and earlier-stage non-small cell lung cancer. Melanoma maintains substantial dependence on PD-L1 assessment because immune checkpoint blockade remains a foundational therapeutic approach. Breast cancer, particularly triple-negative breast cancer, increasingly incorporates PD-L1 testing into treatment selection as immunotherapy indications continue expanding. Diagnostic laboratories account for a substantial proportion of PD-L1 testing because centralized pathology services provide standardized interpretation, quality assurance, and high-throughput testing capabilities. The integration of AI is becoming increasingly important because growing pathology workloads require scalable diagnostic workflows that improve efficiency without compromising analytical quality. AI is supporting automated tissue recognition, standardized PD-L1 scoring, quality control, and clinical reporting within digital pathology environments.

Competitive and Strategic Outlook

The competitive landscape features established pathology diagnostic companies alongside specialized companion diagnostic providers. F. Hoffmann-La Roche remains a global leader in companion diagnostics through its Ventana pathology portfolio and long-standing collaborations with immuno-oncology drug developers, continuing to strengthen automated tissue diagnostics and digital pathology capabilities. Agilent Technologies expands its PD-L1 testing portfolio through Dako companion diagnostic assays that support multiple approved immunotherapies, focusing on assay standardization, laboratory automation, and integrated pathology solutions. Abbott leverages its global diagnostics infrastructure to support precision oncology through molecular and immunodiagnostic technologies, continuing to invest in advanced diagnostic platforms. Thermo Fisher Scientific provides comprehensive pathology instruments, antibodies, reagents, and molecular diagnostic solutions supporting oncology research and clinical laboratories. QIAGEN strengthens precision oncology through molecular diagnostic assays, bioinformatics solutions, and companion diagnostic collaborations. Bio-Rad supports oncology diagnostics through high-quality antibodies, reagents, digital PCR systems, and laboratory quality control products. Bio-Techne focuses on advanced antibodies, multiplex immunoassays, spatial biology, and cell analysis technologies. Merck KGaA supports precision oncology through life science research reagents, antibodies, and laboratory technologies used in biomarker development. Companies are pursuing product portfolio expansion through innovation in automated staining platforms, digital pathology solutions, and AI-enabled interpretation tools. Strategic collaborations between diagnostic manufacturers and pharmaceutical companies are increasing, driven by the need for companion diagnostic development alongside immunotherapies. Recent key developments include Agilent Technologies receiving FDA approval for the expanded use of PD-L1 IHC 22C3 pharmDx on the Dako Omnis platform to identify patients with esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric or gastroesophageal junction adenocarcinoma eligible for treatment with KEYTRUDA. Abbisko Therapeutics and AstraZeneca entered into a strategic collaboration to conduct a Phase I/II trial combining lumipodlin with Tagrisso for patients with EGFR-mutated and PD-L1-positive NSCLC. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing emerging markets. Mergers and acquisitions are occurring as larger players seek to expand market presence and technology capabilities.

Short Conclusion

The PD-L1 testing market is positioned for sustained growth driven by the convergence of immunotherapy expansion, companion diagnostic co-development, and digital pathology innovation. The transition from single-marker companion diagnostics toward integrated immune profiling represents a fundamental shift in precision oncology. While challenges related to assay variability, tissue availability, and implementation costs persist, strategic investments in technology, standardization, and regulatory compliance are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with PD-L1 testing evolving into a foundational biomarker within broader precision oncology platforms that integrate genomic, transcriptomic, and immune profiling to support increasingly personalized cancer treatment strategies.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global PD-L1 Testing Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Biomarker and Disease Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Disease Burden & Unmet Clinical Needs
• 3.8 Epidemiology and Patient Population Analysis
  • 3.8.1 Cancer Incidence
  • 3.8.2 Diagnosed Patient Population
  • 3.8.3 Eligible Population for PD-L1 Testing
• 3.9 Companion Diagnostics Landscape
• 3.10 Biomarker Testing Landscape in Oncology
• 3.11 Testing Volume Analysis
• 3.12 Clinical Adoption Trends

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies
• 6.2 Product Innovation
• 6.3 Clinical Trial Analysis
• 6.4 Pipeline Analysis
• 6.5 Digital Pathology Integration
• 6.6 Artificial Intelligence Integration in PD-L1 Assessment

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Global PD-L1 Testing Market Landscape Analysis

• 8.1 Analysis by Technology Platform
• 8.2 Analysis by Biomarker Type
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Testing Methodology
• 8.5 Analysis by Clinical Application

9. Global PD-L1 Testing Market Segment Analysis (2021-2035)

• 9.1 By Product
  • 9.1.1 Instruments
  • 9.1.2 Assay Kits & Reagents
  • 9.1.3 Software & Image Analysis Solutions
• 9.2 By Technology
  • 9.2.1 Immunohistochemistry (IHC)
  • 9.2.2 Multiplex Immunofluorescence
  • 9.2.3 Other Technologies
• 9.3 By Indication
  • 9.3.1 Lung Cancer
  • 9.3.2 Melanoma
  • 9.3.3 Breast Cancer
  • 9.3.4 Gastric & Gastroesophageal Junction Cancer
  • 9.3.5 Cervical Cancer
  • 9.3.6 Other Cancer Types
• 9.4 By Sample Type
  • 9.4.1 Tissue Biopsy
  • 9.4.2 Liquid Biopsy
• 9.5 By End User
  • 9.5.1 Hospitals
  • 9.5.2 Diagnostic Laboratories
  • 9.5.3 Academic & Research Institutes
  • 9.5.4 Others

10. Global PD-L1 Testing Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global PD-L1 Testing Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 South Korea
• 11.11 India
• 11.12 Australia
• 11.13 Brazil
• 11.14 Saudi Arabia
• 11.15 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd.
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 Agilent Technologies
• 13.3 Hologic, Inc.
• 13.4 Abbott Laboratories
• 13.5 Bio-Techne Corporation
• 13.6 Thermo Fisher Scientific Inc.
• 13.7 Merck KGaA
• 13.8 Bio-Rad Laboratories, Inc.
• 13.9 QIAGEN N.V.
• 13.10 PerkinElmer, Inc.

14. Global PD-L1 Testing Market Commercial Forecast Analysis

• 14.1 PD-L1 IHC 22C3 pharmDx
• 14.2 PD-L1 IHC 28-8 pharmDx
• 14.3 VENTANA PD-L1 (SP142) Assay
• 14.4 VENTANA PD-L1 (SP263) Assay
• 14.5 Other Commercial PD-L1 Testing Assays

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends